Refine by
Sophia Ddm Genomics Redefines The Boundaries Of Fungal Genomics Software Available In In Canada
8 software items found
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Cardiac diseases are the #1 cause of death globally1,2. Genetic testing is frequently considered a key component of the clinical management process of inherited cardiac disorders, such as hypertrophic, dilated, and arrhythmogenic cardiomyopathies, aortopathies, and inherited arrhythmia syndromes3. This approach is typically reserved for patients with a confirmed or suspected diagnosis of an ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Maximize your biologically actionable insights from small tumor samples with the SOPHiA DDM™ RNAtarget Technology end-to-end solutions. Gene fusions have been associated with various tumors and are recognized as valuable cancer biomarkers in cancer research1. Targeted RNA sequencing is recommended to maximize novel fusion detection by identifying transcribed and potentially actionable ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Most rare and inherited diseases have a neurological component, likely because more than 80% of human genes are expressed in the brain.1 Neurological disorders are multifactorial and heterogeneous, meaning that their genetic basis is often poorly understood. Indeed, only 30-50% of neurological disorders have a molecular genetic diagnosis.2 ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Confidently assess genetic variants predisposing to cancer. Hereditary causes account for ∼10% of cancer cases, and an estimated 20% of cancer patients have a family history of cancer.1 Identification of an individual with a suspected hereditable cancer can lead to additional examinations and help formulate the most appropriate prevention strategies. Evaluating the predisposition to develop ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Pioneering Innovation, Streamlining Adoption: We are pushing the boundaries of today’s liquid biopsy capabilities. Bring liquid biopsy to your lab with our streamlined DNA-only NGS workflow, taking you from cell-free DNA sample to comprehensive report in record time. Powered by state-of-the-art proprietary algorithms, the SOPHiA DDMTM Platform reveals deep genomic insights from cell-free ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Identifying patterns of genomic scarring in ovarian cancer samples. Accurate identification and reporting of Homologous Recombination Deficiency (HRD) status are critical for better patient management. SOPHiA DDM Dx HRD Solution is a CE-marked in vitro diagnostic (IVD) application leveraging low-pass Whole Genome Sequencing (WGS) and a proprietary deep-learning algorithm. Powered by the advanced ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Deeper genomic insights, fewer missed opportunities. CGP enables clinical researchers to identify actionable variants and biomarkers across hundreds of genes using a single solution. The SOPHiA DDMTM Platform offers decentralized, in-house next generation sequencing (NGS) applications that help maximize insights from CGP data by leveraging advanced analytical capabilities, intutive interpretation ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Enabling novel fusion detection in small samples to improve lung cancer management. Sensitive novel fusion detection optimized for small lung cancer FFPE biopsies enhance patient care. SOPHiA DDM™ Dx RNAtarget Oncology Solution (ROS) is a CE-marked in vitro diagnostic (IVD) application based on next-generation sequencing (NGS) enabling accurate and sensitive detection of novel ...